anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The present invention relates to an antibacterial active composition for Helicobacter pylori bacteria and a method of preparing the same. The antibacterial active composition may have improved sterilization effects by adding at least one of lactic acid and vitamin C in citric acid to obtain a metal ion, using the metal ion as a reducing agent to form a hydroxyl group (radical), and enabling the hydroxyl group to suppress the activation of enzyme distributed in a cell membrane, thereby weakening the function of the cell membrane, interrupting cellular respiration of Helicobacter pylori bacteria, and suppressing the normal growth of the Helicobacter pylori bacteria. The purpose of the present invention is to provide the antibacterial active composition for Helicobacter pylori bacteria which not only maintains a pleasant oral condition by sterilizing Helicobacter pylori bacteria, thereby removing gum inflammation or halitosis, but also maintains individual hygiene and prevents the generation of gastritis or stomach ulcer by preventing Helicobacter pylori bacteria going into one′s stomach; and the method of preparing the antibacterial active composition. Other purpose of the present invention is to provide the antibacterial active composition for Helicobacter pylori bacteria which can sterilize Helicobacter pylori bacteria by weakening cell membrane permeability and suppressing cell respiration, and a method of preparing the antibacterial active composition for Helicobacter pylori bacteria. The antibacterial active toothpaste composition for Helicobacter pylori bacteria includes at least one of citric acid, lactic acid, and vitamin C, as sterilizing components of the toothpaste composition, added to purified water. The antibacterial active toothpaste composition for Helicobacter pylori bacteria contains 10.0 to 60.0 wt.% of citric acid, 0.1 to 20.0 wt.% of lactic acid, 0.1 to 30.0 wt.% of vitamin C, and the remainder consisting of purified water.
Participants will receive a low intensity version of The Cogmed Working Memory Training Program. This involves undergoing 25 training sessions for 15 minutes per day, 5 days a week for 5 weeks. Participants will also receive weekly phone calls from a CogMed Coach to review progress and adjust the training as needed.
Vaccination with the combination of Ag85B-TB10.4 and IC31 generated a high amount of polyfunctional CD4 + T cells expressing high levels of IFN-γ, TNF-α, and IL-2. This in turn led to significant protection against infection with  M .  tuberculosis  in the mouse aerosol challenge model of tuberculosis. Importantly, our results also showed that both the irnmuno- genicity of the vaccine and its ability to protect against TB infection was highly dependent on the antigen dose. Thus, whereas the standard antigen dose of 5.0μg, as well as 15.0μg, did not induce significant protection against  M .  tuberculosis , reducing the dose to 0.5 μg increased both the immunogenicity of the vaccine as well as its protective efficacy to a level comparable to that observed in BCG vaccinated mice. Thus, the adjuvant IC31®, with the optimal antigen dose, can induce a strong protective Th1 response against  M .  tuberculosis .
The purpose of this randomized, placebo-controlled, three-condition, double-blind, within-participants crossover clinical trial is to determine and compare the effects of the combination of TeaCrine® and caffeine to a placebo and a caffeine condition on measures of cognitive performance, cardio-autonomic, and hemodynamic responses after a physically demanding protocol. After giving informed consent, 20 ROTC members or tactical personnel will undergo baseline performance testing and familiarization and will then be randomly assigned to order of completion of the placebo (P), caffeine (C) condition, and caffeine + TeaCrine (CT) condition, with each session separated by at least 96 hours. In each condition, Participants will be given the condition pill assigned to them, the pill will be taken orally with water, and will wait 60 minutes. At this time, the Participant will complete a treadmill-based physically fatiguing interval protocol with select cognitive testing during the exercise recovery intervals. Participant measures of mental fatigue will be assessed pre- and post-testing, and following the interval bout participants will perform a series of cognitive tasks. Heart rate variability (HRV) and respiration will be assessed continuously though these tasks and blood pressure will be assessed at baseline, prior to the exercise bout, immediately following the exercise bout, and following the cognitive testing.
The present study will compare the nutritional responses to two 4-month weight loss programs inducing the same energy deficit in obese adolescents, one based on exercise and the other one using dietary restriction. After a first 4-month phase stabilizing the adolescents' daily energy intake and expenditure, half of the sample with increase their physical activity to induce a 10% increase of their daily energy expenditure (maintaining the same energy intake) while the other half will stick with the same physical activity program but reduce their daily intake to match for the same 10% energy deficit. Before, at the end and 4 months after the intervention, Investigator will assess the adolescents' energy intake and appetite control by measuring: ad libitum energy intake, appetite feelings throughout the day, food preferences, food reward. But also all the potential underneath mechanisms based on gastro-peptides and adipokines. Finally, sleep metabolism will be assessed using polysomnography as a potential link between weight loss and appetite control. Body composition, quality of life, aerobic capacities and resting metabolic rate will also be measured at each time point.
Participants will have individualised model-based intermittent vancomycin dosing using the Vanc App dosing calculator (as used in VANC APP Part 1, see clinicaltrials.gov ID: NCT04044703). A first-dose trough concentration will be measured for each participant and the clinician will then enter that concentration into the web application ('First-dose trough dose adjustment calculator'). A dose adjustment will be generated by the calculator if the predicted steady-state level is outside of target range. If the predicted steady-state level is within target range (10-20mg/L) the calculator will recommend continuing with the same dose. The vancomycin concentration is then measured at steady state to determine if the target concentration has been achieved.
Compounds UCF1 and derivatives thereof exhibit anti-bacterial and anti-tumour activities and may be used for the preparation of anti-bacterial and anti-tumour agents.     Compounds UCF1 may be produced by fermentation of a microorganism of the genus Streptomyces capable of producing compounds UCF1, preferably Streptomyces sp. UOF1 (FERM BP-2844) and recovering the desired compounds from the cultured broth.     The compounds UCF1 have the formula (see fig. I)             (I) [wherein R represents either (see fig. II) or (see fig. III) The compounds may be oxidised to obtain derivatives of formula (see fig. IV) which exhibit similar pharmacological activities.
PROBLEM TO BE SOLVED: To obtain a medicine useful for a preventive and a therapeutic agent for hyperlipemia, hyperglycemia and diseases caused by insulin resistance, containing a condensed heterocyclic compound. SOLUTION: A compound of formula I (X is a benzimidazole ring group; Y is an oxygen atom or a sulfur atom; Z is a group of formula II, etc.; R is H, a 1-4C alkyl, a 1-4C alkoxy, etc.; (m) is 1-5) contained as an active ingredient in the objective medicine is produced by reducing a compound of the formula, X-(CH2 )m-1 -CO2 R' (R' is a 1-5C alkyl) to give a compound of the formula, X-(CH2 )m -OH. The reaction is carried out usually in the presence of a solvent such as C6 H6 under cooling to under heating generally for 0.5 hour to several days. Then the compound of the formula, X-(CH2 )m -OH is reacted with a compound of formula III [Z' is a group of formula IV (Tr is triphenylmethyl) at room temperature of under heating for several hours to several days according top optical extension reaction to give a compound of formula V.  Then the compound of formula V is reacted with an acid such as HCl under cooling with ice or under heating usually for tens minutes tens hours to give the compound of formula I.
Infants with cyanotic congenital heart disease undergoing surgery in the neonatal period have a high rate of brain injury resulting in seizures, stroke, cerebral palsy, and neurodevelopmental delays. Neuroimaging abnormalities are found in 30% to 60% of cases and neurodevelopmental impairments occur in more than half of these children. The mechanisms of brain injury in these children are not fully understood. Experimental animal models have shown that the abundant release of glutamate in the brain during hypoxic-ischemic insult results in brain injury. Blocking glutamate receptors by administration of the anticonvulsant topiramate has been shown to prevent such injury in animal studies. This study is an open pilot trial of peri-operative topiramate administration to infants with cyanotic congenital heart disease to test the feasibility of this approach and generate preliminary data about markers of brain injury (serum S100B levels and urine metabolomics) and neurodevelopment at 18 months of age. If the approach is feasible and the preliminary data are encouraging a larger efficacy trial will be designed. Although topiramate has been used in neonates and infants to treat seizures and in a pilot study in term infants with hypoxic-ischemic encephalopathy, this is the first study of its effects on markers of brain injury and neurologic outcomes in infants with cyanotic congenital heart disease.
BACKGROUND: Community-acquired pneumonia (CAP) is a common and serious condition that can be caused by a variety of pathogens. However, much remains unknown about how these pathogens interact with the lower respiratory commensals, and whether any correlation exists between the dysbiosis of the lower respiratory microbiota and disease severity and prognosis.
METHODS: We conducted a retrospective cohort study to investigate the composition and dynamics of sputum microbiota in patients diagnosed with CAP. In total, 917 sputum specimens were collected consecutively from 350 CAP inpatients enrolled in six hospitals following admission. The V3-V4 region of the 16 S rRNA gene was then sequenced.
RESULTS: The sputum microbiota in 71% of the samples were predominately composed of respiratory commensals. Conversely, 15% of the samples demonstrated dominance by five opportunistic pathogens. Additionally, 5% of the samples exhibited sterility, resembling the composition of negative controls. Compared to non-severe CAP patients, severe cases exhibited a more disrupted sputum microbiota, characterized by the highly dominant presence of potential pathogens, greater deviation from a healthy state, more significant alterations during hospitalization, and sparser bacterial interactions. The sputum microbiota on admission demonstrated a moderate prediction of disease severity (AUC = 0.74). Furthermore, different pathogenic infections were associated with specific microbiota alterations. Acinetobacter and Pseudomonas were more abundant in influenza A infections, with Acinetobacter was also enriched in Klebsiella pneumoniae infections.
CONCLUSION: Collectively, our study demonstrated that pneumonia may not consistently correlate with severe dysbiosis of the respiratory microbiota. Instead, the degree of microbiota dysbiosis was correlated with disease severity in CAP patients.
The subjects will be randomized to placebo plus aspirin 81 mg orally daily for 14 days. The study drug (i.e., placebo) will then be discontinued and aspirin continued for another 43 days.
This is the fluoroscopy protocol used routinely in most catheterization labs in the region. This includes fluoroscopy and cine image acquisition at 15 frames per second (FPS) at 8-inch mode. Virtual collimation and last image hold (LIH) will be used as needed. This protocol will be implemented for 6 weeks.
BACKGROUND: Health policies form the foundation for provisioning best level care and are important for all stakeholders including patients and healthcare providers. Health policy analysis and evaluation allows policy makers to improve an existing policy, terminate a non-effective policy and to successfully implement future policies.The objective was to assess the coherence between the two local policy documents on NCD prevention and control in Sri Lanka, the national NCD policy (NCD policy) and the multisectoral action plan (MSAP), and to assess the consistency of MSAP with the global action plan for NCDs.
METHODS: The content analysis of the NCD policy and MSAP of Sri Lanka was conducted based on the modified criteria developed to the 'Analysis of determinants of policy impact' model, by two reviewers independently. Coherence between MSAP and the global NCD action plan were also assessed by two reviewers independently. Consensus for discrepancy was achieved through discussion.
RESULTS: Accessibility was the strongest criteria for the NCD policy, while, resources and obligations were the weakest. Goals and monitoring and evaluation criteria were the strongest in the MSAP. Requirement for improvement were identified in policy background, goals, monitoring and evaluation, and public opportunities for the NCD policy. Accessibility, policy background, resources, public opportunities and obligations require further improvement in the MSAP. The MSAP is well coherent with the global road map for NCD prevention and control.
CONCLUSION: Policy documents related to NCD prevention and control in Sri Lanka are coherent with the global action plan, while, there are areas within the local policy documents that need to be improved to enhance the coherence between the local documents. Lessons learnt by this activity need to be utilized by Sri Lanka and other countries to improve the uniformity between the NCD policy documents within the country as well as internationally.
The invention relates to a—in particular—hydrous, sweat-absorbing cosmetic product, e.g. a deodorant, containing a sweat-absorbing complex. The invention also relates to a method for the production of said complex and said cosmetic product. The cosmetic product of the invention includes i) a base formulation, and ii) a sweat-absorbing complex comprising (a) at least one water-absorbing component, (b) at least one surface-active agent, c) at least one electrolyte, and (d) at least one solvent and/or at least one vehicle. The sweat-absorbing complex in the base formulation is present in the form of emulsified particles. The particles consist of a three-dimensional, water-swellable network of said at least one water-absorbing component and are at least partially covered with said at least one surface-active agent. Said at least one electrolyte is incorporated at least partially in the interstices of the three-dimensional network of said at least one water-absorbing component.
The invention discloses a double-protein co-emulsification system, a preparation method and an application thereof. The double-protein co-emulsification system is prepared from 0.5-5 wt% of proteins, and grease and water, wherein a volume ratio of the grease to the water is 2-15:85-98. The preparation method includes following steps: dissolving the proteins in water for enabling the protein to be hydrated fully; and adding the grease with shearing and homogenization. The double-protein co-emulsification system has an excellent stability, is free of phenomena, such as oil separation, layering, precipitation, flocculation and the like, after being stored for a long time, and is free of any bad odor. The double-protein co-emulsification system is free of extra addition of any emulsifier and stabilizing agents and is free of adjustment of pH value of a product. The preparation method is simple, is easy-to-control in technology parameters, is economical and easy to carry out and is suitable for industrialized production. The double-protein co-emulsification system also can be used for preparing enteral nutrition preparations, health-caring foods, medicine preparations, beverages or cosmetics, and especially is suitable for preparing the enteral nutrition preparations.
Patients undergoing hip/knee replacements or colorectal surgery will be recruited and tested on 3 occasions: pre-op, post-op and at follow-up. POCD status will be determined at post-op and follow up. Cognitive function, zinc status, POCD biomarkers and inflammatory markers will be measured on all 3 occasions.
OBJECTIVE: Although keyhole transorbital approaches are gaining traction, their indications have not been adequately studied comparatively. In this study the authors have defined them also as transwing approaches-meaning that they use the different facies of the sphenoid wing for cranial entry-and sought to compare the four major ones: 1) lateral orbitocraniotomy through a lateral canthal incision (LatOrb); 2) modified orbitozygomatic approach through a palpebral incision (ModOzPalp); 3) modified orbitozygomatic approach through an eyebrow incision (ModOzEyB); and 4) supraorbital craniotomy through an eyebrow incision (SupraOrb), coupled with its expanded version (SupraTransOrb).
METHODS: Cadaveric dissections were performed at the neuroanatomy lab. To delineate the skull base exposure, four formalin-fixed heads were used, with two sides dedicated to each approach. The outer limits were assessed via image guidance and were mapped and illustrated accordingly. A fifth head was dissected purely endoscopically, just to facilitate an overview of the transwing concept. Qualitative features were also rigorously examined.
RESULTS: The LatOrb proves to be more versatile in the middle cranial fossa (MCF), whereas the anterior cranial fossa (ACF) exposure is limited to a small area above the sphenoid ridge. An anterior clinoidectomy is possible; however, the exposure of the roof of the optic canal is suboptimal. The ModOzPalp adequately exposes both the ACF and MCF. Its lateral trajectory allows the inferior to superior view, yet there is restricted access to the medial anterior skull base (olfactory groove). The ModOzEyB also provides extensive exposure of the ACF and MCF, but has a more superior to inferior trajectory compared to the ModOzPalp, making it more appropriate for pathology reaching the medial anterior skull base or even the contralateral side. The anterior clinoidectomy is performed with improved visualization of the optic canal. The SupraOrb provides mainly anterior cranial base exposure, with minimal middle fossa. An anterior clinoidectomy can be performed, but without any direct observation of the superior orbital fissure. Some MCF access can be accomplished if the lateral sphenoid wing is drilled inferiorly, leading to its highly versatile variant, the SupraTransOrb.
CONCLUSIONS: All the aforementioned approaches use the sphenoid wing as skull base corridor from a specific orientation point; hence these are designated as transwing approaches. Their peculiarities mandate careful case selection for the effective and safe completion of the surgical goals.
A randomized controlled clinical trial will be conducted in Rajaie Cardiovascular Center in Tehran, Iran. After review of the inclusion and exclusion criteria and explanation of the design of the study, written consent form will be completed. The participants are 50 eligible coronary artery disease patients, aged 30-75 years. Intervention group will be received a heart-healthy diet with a specified number of food servings from different food groups (including vegetables, fruits, grains, dairy products, meats) + daily consumption of 30 grams of flaxseed + 25 mL/day of refined olive oil (equivalent to 4 tablespoons; 2 tablespoons for lunch and 2 tablespoons for dinner); and control group will be received recommendations for a heart-healthy diet, such as those of the American Heart Association for 3 months. These include eating at least 5 servings of vegetables and fruits daily, reduction in the consumption of sources of saturated and trans fats by avoiding the consumption of high-fat red meats and replacing them with low-fat meat or with poultry and fish, replacing low-fat dairy sources with regular or high-fat ones; consumption of regular vegetable oils such as canola and sunflower; reduction in salt consumption; and reduction in the consumption of simple sugars, for 3 months. Flow mediated dilatation (FMD) in brachial artery via ultrasonography, plasma levels of lipids and lipoproteins via enzymatic method, and fatty acids composition of red blood cells via gas chromatography method were measured.
Timely and accurately seizure detection is of great importance for the diagnosis and treatment of epilepsy patients. Existing seizure detection models are often complex and time-consuming, highlighting the urgent need for lightweight seizure detection. Additionally, existing methods often neglect the key characteristic channels and spatial regions of electroencephalography (EEG) signals. To solve these issues, we propose a lightweight EEG-based seizure detection model named lightweight inverted residual attention network (LRAN). Specifically, we employ a four-stage inverted residual mobile block (iRMB) to effectively extract the hierarchical features from EEG. The convolutional block attention module (CBAM) is introduced to make the model focus on important feature channels and spatial information, thereby enhancing the discrimination of the learned features. Finally, convolution operations are used to capture local information and spatial relationships between features. We conduct intra-subject and inter-subject experiments on a publicly available dataset. Intra-subject experiments obtain 99.25% accuracy in segment-based detection and 0.36/h false detection rate (FDR) in event-based detection, respectively. Inter-subject experiments obtain 84.32% accuracy. Both sets of experiments maintain high classification accuracy with a low number of parameters, where the multiply accumulate operations (MACs) are 25.86[Formula: see text]M and the number of parameters is 0.57[Formula: see text]M.
A method, device, and computer program storage product for generating a query to extract clinical features into a set of electronic medical record (EMR) tables based on clinical knowledge. A knowledge tree is constructed according to a set of clinical knowledge data. An EMR graph corresponding to a set of EMR tables is obtained. The EMR graph comprises at set of table nodes and a set of attribute nodes. The set of table nodes and the set of attribute nodes represent a structure of each EMR table in the set of EMR tables and a reference relationship among attributes of set of EMR tables. A plurality of sub-queries is generated based on the knowledge tree and the EMR graph. At least one query is generated by combining the plurality of sub-queries according to the knowledge tree.
PROBLEM TO BE SOLVED: To obtain an antimycotic agent consisting of a new benzylamine derivative and physiologically allowable salt thereof, useful as the antimycotic agent, and having a new mother nucleus having an antimycotic activity. SOLUTION: This antimycotic agent is a benzylamine derivative of formula I [R1 , R4 are each H or a 6-18C aromatic hydrocarbon allowed to have a substituent; R2 , R3 are each a 1-4C alkyl; (m), (n) are each 1-4] and physiologically allowable salt thereof, e.g. 4-tert-butyl-N-methyl-N-(2-phenylbenzyl)benzylamine of formula II. The compound of formula I is obtained by reacting a corresponding benzyl halide or benzoyl halide with N-methylbenzylamine derivative derived from a benzoic acid derivative, and in the case of using the benzoyl halide, reducing by lithium aluminum hydride., etc. The compound of the formula I is most preferably used as a dermal agent for external use. Also the compound is preferably used by spinning after melting with blending in a process of producing a fiber or impregnating to a cloth. For a plastic product, it is preferable to melt and mix therewith.